CN106872698A - A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase - Google Patents
A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase Download PDFInfo
- Publication number
- CN106872698A CN106872698A CN201710103206.0A CN201710103206A CN106872698A CN 106872698 A CN106872698 A CN 106872698A CN 201710103206 A CN201710103206 A CN 201710103206A CN 106872698 A CN106872698 A CN 106872698A
- Authority
- CN
- China
- Prior art keywords
- pla2
- reagents
- detection kit
- lase
- activating factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of quantitative immunological and suppresses detection kit and application that method determines platelet-activating factor acetylhydro-lase, and the detection kit includes Lp PLA2 R1 reagents and Lp PLA R2 reagents；Wherein, the component of the Lp PLA2 R1 reagents includes buffer substance to, preservative and water；The component of the Lp PLA2 R2 reagents includes buffer substance, anti-human LP PLA2 enzyme activities antibody, 1 myristoyl 2 (4 nitrobenzophenone succinyl) lecithin, 1 sodium nonanesulfonate, vitamin E, preservative and water.Detection kit of the present invention platelet-activating factor acetylhydro-lase content can carry out context of detection application in sample.Detection kit of the present invention has the characteristics of good stability, testing efficiency are high, test result is accurate, sensitivity is high.
Description
Technical field
The invention belongs to vitro detection reagent technique field, and in particular to a kind of quantitative immunological suppresses method and determines lipoprotein phase
Close detection kit and the application of phospholipase A2.
Background technology
Platelet-activating factor acetylhydro-lase（Lp-PLA2）Be cause in recent years extensive concern a kind of and atherosclerosis and
The closely related phospholipase A2 superfamily member of ischemic angiocardiopathy and cerebrovascular disease, it can be as a kind of new inflammatory reaction mark
The independent risk factor of thing and prediction cardiovascular and cerebrovascular disease.
The detection method of Lp-PLA2 has two kinds of enzyme biochemical measurement and immune quality determination in currently available technology；The former enzyme
Biochemical assay is set up based on Lp-PLA2 enzymatic activitys catalytic substrate, with Lp-PLA2 activity in immediate reaction serum
Advantage, but the method detection architecture be vulnerable to other enzymes of phosphatide enzyme family or isodynamic enzyme, the interference of detection environment and influence detection
As a result；The immune quality determination method of the latter is the quality for being based on the antigen and antibody specific principle reacted and determining Lp-PLA2, its tool
There is high specific but cannot be distinguished from the enzyme and metabolite of inactivation, so as to cannot reflect the Lp-PLA2's with bioactivity
Real content；Therefore all there is certain weak point in two kinds of current detection methods, and the difference of methodology causes both in phase
With the detection difference in sample substantially, testing result accuracy is not high.
The content of the invention
For deficiencies of the prior art, the technical problem to be solved in the present invention is：How to provide a kind of quantitative
Immunodepression determines detection kit and the application of platelet-activating factor acetylhydro-lase, makes it have good stability, testing efficiency
It is high, the characteristics of test result is accurate, sensitivity is high, can solve the problem that what the detection method of existing Lp-PLA2 was present is easily subject to outer
Boundary's interference effect and cause testing result inaccurate, or the skill of the real content of the Lp-PLA2 with bioactivity cannot be reflected
Art problem.
In order to solve the above-mentioned technical problem, the present invention is adopted the following technical scheme that：A kind of quantitative immunological suppresses method and determines fat
The detection kit of albumen associated phospholipase A2, including Lp-PLA2 R1 reagents and Lp-PLA R2 reagents；Wherein, the Lp-
The component of PLA2 R1 reagents includes buffer substance to, preservative and water；The component of the Lp-PLA2 R2 reagents includes cushion
Matter, anti-human LP-PLA2 enzyme activities antibody, 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin, 1- sodium nonanesulfonates, dimension
Raw element E, preservative and water.
Further, buffer substance described in the Lp-PLA2 R1 reagents is to being potassium dihydrogen phosphate and dipotassium hydrogen phosphate；Institute
Preservative is stated for proclin 300.
Further, by potassium dihydrogen phosphate, dipotassium hydrogen phosphate, proclin 300 and water according to 1.5 ~ 3.6 g：0.8~2.4
g：20 μL：The mass volume ratio mixing of 100 mL, is configured to the Lp-PLA2 R1 reagents.
Used as optimization, the anti-human LP-PLA2 antibody is the anti-human LP-PLA2 enzyme activities antibody in mouse source, the anti-human LP- in rabbit source
The anti-human LP-PLA2 enzyme activities antibody of PLA2 enzyme activities antibody or sheep source.
Used as another optimization, buffer substance described in the Lp-PLA2 R2 reagents is citric acid, and the preservative is
proclin300。
As further optimization, by 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin, anti-human LP-PLA2 enzyme activity
Body, citric acid, 1- sodium nonanesulfonates, vitamin E, proclin 300 and water are resisted strenuously according to 0.25 ~ 0.8 g：0.5~2 mg：
0.03~0.2 g：0.04~0.2 g：0.02~0.06 g：20 μL：After the mass volume ratio mixing of 100 mL, mixed solution is adjusted
PH to 5.00 ~ 7.00, with the prepared Lp-PLA2 R2 reagents.
Above-mentioned detection kit platelet-activating factor acetylhydro-lase content in sample carries out the application of context of detection.
Compared to existing technology, the present invention has the advantages that：
1st, the present invention provides a kind of kit based on immune detection and the biochemical detection technique for combining of enzyme, and principle is to be tried in detection
Using the monoclonal antibody for suppressing Lp-PLA2 enzymatic activitys in the reagent of agent box, it can specifically recognize and block Lp-PLA2 enzymes
Activity, by the repressed enzymatic activity of enzyme biochemical measurement, can accurately determine Lp-PLA2 enzymatic activitys, fat in complete paired samples
Albumen associated phospholipase A2 is detected that the method has the advantage of enzyme biochemical measurement and immune quality determination concurrently, solves existing Lp-
What the detection method of PLA2 was present is easily influenceed by external interference and causes testing result inaccurate, or cannot reflect with life
The technical problem of the real content of the Lp-PLA2 of thing activity, for the clinical detection of Lp-PLA2 and application study provide relatively reliable
Technological means.
2nd, detection kit of the present invention has good stability, and testing efficiency is high, and test result is accurate, high excellent of sensitivity
Point, experiment proves that, using minimum 0.0018 A/nmol/min/mL of detection kit sensitivity for analysis of the present invention, detection limit
Low, precision reaches 3.08%, can exactly repeat result of the test, experimental result is more prepared reliability.
3rd, detection kit of the present invention has the advantages that simple to operate, quick, accuracy is high, high degree of automation, is applicable
In clinically widely using, quantitative determination particularly can be realized to emergency treatment.
Specific embodiment
The present invention is described in further detail with reference to specific embodiment.The implementation case is premised on the technology of the present invention
Under implemented, it is creative to illustrate the present invention now to provide detailed implementation method and specific operating process, but this hair
Bright protection domain is not limited to following embodiment.
The raw material 1- sodium nonanesulfonates used in the following embodiments of the present invention are produced for Sigma Co., USA, and 1- myristoyls-
2- (4- nitrobenzophenones succinyl) lecithin is produced for Avanti companies of the U.S., and anti-human LP-PLA2 enzyme activities antibody is auspicious by Shanghai
Hundred million Bioisystech Co., Ltd are produced, and proclin 300 is produced by Sigma Co., USA, other the general chemical reagent for using
The pure rank of analysis is, the detecting instrument used in detection method is Bechkman AU480 automatic clinical chemistry analyzers.
Anti-human LP-PLA2 enzyme activities antibody described in following embodiments is the anti-human LP-PLA2 antibody in mouse source, from mouse source
The immunogenicity of anti-human LP-PLA2 antibody, antigen-binding affinity, serum half-life are even more ideal, with the LP- in serum
PLA2 specific binding capacities are high, can greatly improve the accuracy of detection.But anti-human LP-PLA2 described in following examples
Enzyme activity antibody still can be resisted strenuously using the anti-human LP-PLA2 enzyme activity of the anti-human LP-PLA2 enzyme activities antibody in rabbit source or sheep source
Body, it is also possible to reach identical testing goal, do not repeat one by one herein.
Embodiment 1
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 1.5
Gram, 0.8 gram of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.25
Gram, anti-human 0.5 milligram of LP-PLA2 enzyme activities antibody, 0.03 gram of citric acid, 0.04 gram of 1- sodium nonanesulfonates, vitamin E 0.02
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 2
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.0
Gram, 1.2 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.25
Gram, anti-human 0.5 milligram of LP-PLA2 enzyme activities antibody, 0.03 gram of citric acid, 0.04 gram of 1- sodium nonanesulfonates, vitamin E 0.02
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 3
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.25
Gram, anti-human 0.5 milligram of LP-PLA2 enzyme activities antibody, 0.03 gram of citric acid, 0.04 gram of 1- sodium nonanesulfonates, vitamin E 0.02
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 4
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 3.0
Gram, 2.0 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.25
Gram, anti-human 0.5 milligram of LP-PLA2 enzyme activities antibody, 0.03 gram of citric acid, 0.04 gram of 1- sodium nonanesulfonates, vitamin E 0.02
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 5
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 3.6
Gram, 2.4 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.25
Gram, anti-human 0.5 milligram of LP-PLA2 enzyme activities antibody, 0.03 gram of citric acid, 0.04 gram of 1- sodium nonanesulfonates, vitamin E 0.02
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 6
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.5
Gram, anti-human 1.0 milligrams of LP-PLA2 enzyme activities antibody, 0.08 gram of citric acid, 0.08 gram of 1- sodium nonanesulfonates, vitamin E 0.04
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 7
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.5
Gram, anti-human 1.0 milligrams of LP-PLA2 enzyme activities antibody, 0.08 gram of citric acid, 0.08 gram of 1- sodium nonanesulfonates, vitamin E 0.04
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 8
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.8
Gram, anti-human 1.5 milligrams of LP-PLA2 enzyme activities antibody, 0.13 gram of citric acid, 0.12 gram of 1- sodium nonanesulfonates, vitamin E 0.06
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 9
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.8
Gram, anti-human 2.0 milligrams of LP-PLA2 enzyme activities antibody, 0.2 gram of citric acid, 0.2 gram of 1- sodium nonanesulfonates, 0.06 gram of vitamin E,
The 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 5.00 with 0.1MNaOH, are made into Lp-PLA2 R2
Reagent.
R1 reagents and R2 reagents are supported the use.
Embodiment 10
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.8
Gram, anti-human 1.5 milligrams of LP-PLA2 enzyme activities antibody, 0.13 gram of citric acid, 0.12 gram of 1- sodium nonanesulfonates, vitamin E 0.06
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 6.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
Embodiment 11
A kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, by Lp-PLA2 R1 reagents and
Lp-PLA R2 reagents are constituted；Wherein, the Lp-PLA2 R1 reagents are adopted and obtained with the following method：Weigh potassium dihydrogen phosphate 2.4
Gram, 1.6 grams of disodium hydrogen phosphate, the 20uL of proclin 300 are dissolved in 100 milliliters of purified waters, are made into LP-PLA2 R1 reagents；Institute
State Lp-PLA2 R2 reagents and adopt and obtain with the following method：Weigh 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin 0.8
Gram, anti-human 1.5 milligrams of LP-PLA2 enzyme activities antibody, 0.13 gram of citric acid, 0.12 gram of 1- sodium nonanesulfonates, vitamin E 0.06
Gram, the 20ul of proclin 300 are dissolved in 100 milliliters of purified waters, adjust solution to pH 7.00 with 0.1MNaOH, are made into Lp-PLA2
R2 reagents.
R1 reagents and R2 reagents are supported the use.
The RATE that the analysis method that kit of the present invention is used often is used for biochemical instruments（Performance rate method）, ladder is first prepared during detection
The platelet-activating factor acetylhydro-lase mark product solution for spending series is measured and computation rate, sets up concentration-speed standard curve, then
Sample is detected, the rating results that will be detected substitute into standard curve, calculate platelet-activating factor acetylhydro-lase in sample
Content.Specific method is：
1st, it is R1, R2 reagent in kit of the present invention is supporting loaded on Beckman Kurt AU480 full automatic biochemical apparatus respectively
Reagent bottle, is put into R1 the and R2 agent bins of AU480, waits operation；
2nd, test sample is loaded into specimen cup, is put into AU480 sample introduction tracks；
3rd, by parameter setting instrument used below：
Use parameter when table 1 is detected
| Reagent volume ratio（Sample：R1 reagents：R2 reagents） | 2:240:80 |
| Master/slave wavelength | 405nm/505nm |
| Read point | 14-27 |
| Analysis method | RATE |
| Calibration type | MB |
| Factor | 12638 |
4th, instrument is run；
5th, output result is recorded.
Using above-mentioned detection method, sensitivity for analysis, precision and stabilization to the detection kit of above-described embodiment 1 ~ 11
Property is detected, as a result as shown in table 1 below：
The test result of table 2
By upper table 2 as can be seen that platelet-activating factor acetylhydro-lase detection kit of the present invention has sensitivity for analysis high, precision
Property and stability, wherein, the combination property of the detection kit of embodiment 10 is best.
Finally illustrate, the above embodiments are merely illustrative of the technical solutions of the present invention and it is unrestricted, although with reference to compared with
Good embodiment has been described in detail to the present invention, it will be understood by those within the art that, can be to skill of the invention
Art scheme is modified or equivalent, and without deviating from the objective and scope of technical solution of the present invention, it all should cover at this
In the middle of the right of invention.
Claims (7)
1. a kind of quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase, it is characterised in that including Lp-
PLA2 R1 reagents and Lp-PLA R2 reagents；Wherein, the component of the Lp-PLA2 R1 reagents includes buffer substance to, preservative
And water；The component of the Lp-PLA2 R2 reagents includes buffer substance, anti-human LP-PLA2 enzyme activities antibody, 1- myristoyls -2-
(4- nitrobenzophenones succinyl) lecithin, 1- sodium nonanesulfonates, vitamin E, preservative and water.
2. quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase according to claim 1, and it is special
Levy and be, buffer substance is to being potassium dihydrogen phosphate and dipotassium hydrogen phosphate described in the Lp-PLA2 R1 reagents；The preservative
It is proclin 300.
3. quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase according to claim 2, and it is special
Levy and be, by potassium dihydrogen phosphate, dipotassium hydrogen phosphate, proclin 300 and water according to 1.5 ~ 3.6 g：0.8~2.4 g：20 μL：
The mass volume ratio mixing of 100 mL, is configured to the Lp-PLA2 R1 reagents.
4. quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase according to claim 1, and it is special
Levy and be, the anti-human LP-PLA2 antibody is the anti-human LP-PLA2 enzyme activities antibody in mouse source, the anti-human LP-PLA2 enzyme activities in rabbit source
The anti-human LP-PLA2 enzyme activities antibody of antibody or sheep source.
5. quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase according to claim 1, and it is special
Levy and be, buffer substance described in the Lp-PLA2 R2 reagents is citric acid, the preservative is proclin300.
6. quantitative immunological suppresses the detection kit that method determines platelet-activating factor acetylhydro-lase according to claim 5, and it is special
Levy and be, by 1- myristoyls -2- (4- nitrobenzophenones succinyl) lecithin, anti-human LP-PLA2 enzyme activities antibody, citric acid, 1-
Sodium nonanesulfonate, vitamin E, proclin 300 and water are according to 0.25 ~ 0.8 g：0.5~2 mg：0.03~0.2 g：0.04~0.2
g：0.02~0.06 g：20 μL：After the mass volume ratio mixing of 100 mL, the pH to 5.00 ~ 7.00 of mixed solution is adjusted, prepared
Obtain the Lp-PLA2 R2 reagents.
7. any detection kit platelet-activating factor acetylhydro-lase content in sample is detected in claim 1 ~ 6
The application of aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710103206.0A CN106872698A (en) | 2017-02-24 | 2017-02-24 | A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710103206.0A CN106872698A (en) | 2017-02-24 | 2017-02-24 | A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106872698A true CN106872698A (en) | 2017-06-20 |
Family
ID=59168432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710103206.0A Pending CN106872698A (en) | 2017-02-24 | 2017-02-24 | A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106872698A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108562749A (en) * | 2018-04-09 | 2018-09-21 | 浙江伊利康生物技术有限公司 | A kind of platelet-activating factor acetylhydro-lase detection reagent |
| CN112710651A (en) * | 2021-01-20 | 2021-04-27 | 浙江夸克生物科技有限公司 | Determination kit for lipoprotein-associated phospholipase A2 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103675282A (en) * | 2013-11-27 | 2014-03-26 | 新昌县美迪生物科技有限公司 | Quantitative bone alkaline phosphatase detection kit and application thereof |
| CN104316689A (en) * | 2014-10-27 | 2015-01-28 | 南京医科大学第一附属医院 | Myeloperoxidase quantitative determination method and detection reagent |
-
2017
- 2017-02-24 CN CN201710103206.0A patent/CN106872698A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103675282A (en) * | 2013-11-27 | 2014-03-26 | 新昌县美迪生物科技有限公司 | Quantitative bone alkaline phosphatase detection kit and application thereof |
| CN104316689A (en) * | 2014-10-27 | 2015-01-28 | 南京医科大学第一附属医院 | Myeloperoxidase quantitative determination method and detection reagent |
Non-Patent Citations (1)
| Title |
|---|
| 韩志均等: "《临床化学常用项目自动分析法（第3版）》", 31 August 2005 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108562749A (en) * | 2018-04-09 | 2018-09-21 | 浙江伊利康生物技术有限公司 | A kind of platelet-activating factor acetylhydro-lase detection reagent |
| CN112710651A (en) * | 2021-01-20 | 2021-04-27 | 浙江夸克生物科技有限公司 | Determination kit for lipoprotein-associated phospholipase A2 |
| CN112710651B (en) * | 2021-01-20 | 2023-10-13 | 浙江夸克生物科技有限公司 | Assay kit for lipoprotein-associated phospholipase A2 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103033629B (en) | Lipoprotein phospholipase A2 assaying reagent and preparation method thereof | |
| CN107817354A (en) | A kind of chemiluminescence detection kit of interleukin 6 and preparation method thereof | |
| CN108398550B (en) | Composition, chip, preparation method of chip and detection device comprising chip | |
| CN105431728A (en) | Method of agglutination immunoassay | |
| CN105352958A (en) | Detection reagent kit for overall 25-hydroxy-vitamin-D | |
| CN105785043A (en) | Kit for quantitatively detecting AFP-L3% | |
| CN112014577B (en) | Kit for improving GPC3 detection sensitivity and preparation method thereof | |
| CN108088839B (en) | A kind of microdose urine protein/urine creatinine detection kit | |
| CA2979559A1 (en) | Prostate antigen standards and uses thereof | |
| JP2018536873A (en) | Method and reagent kit for measuring the biological activity of methionine adenosyltransferase (MAT) | |
| CN106872698A (en) | A kind of quantitative immunological suppresses detection kit and the application that method determines platelet-activating factor acetylhydro-lase | |
| CN109188003A (en) | The method for measuring 25-hydroxy-vitamin D | |
| CN110596405A (en) | Kit for detecting content of heart-type fatty acid binding protein by latex enhanced immunoturbidimetry | |
| CN107102140A (en) | A kind of glutamic acid decarboxylase antibody chemical luminescence immunity detection reagent and preparation method thereof | |
| CN109188002A (en) | For measuring the kit of 25-hydroxy-vitamin D | |
| CN104673878B (en) | Kit for measuring concentration ratio of glycated albumin and albumin by virtue of single system | |
| CN112485447B (en) | Kit for determining complement C1q | |
| CN109490555A (en) | A kind of kit, method and application based on chemoluminescence method detection Lp-PLA2 and CRP content | |
| CN115201183A (en) | Single S100 beta protein chemiluminescence assay kit and assay method thereof | |
| CN109655615A (en) | A kind of complete homogeneous determination lipoprotein associated phospholipase A2Detection kit and its method | |
| CN106324234B (en) | Neu 5 Ac aldolase of modification and its preparation method and application | |
| CN113607950A (en) | Simoa kit of biomarker FOLR1 and use method thereof | |
| CN107860930A (en) | The immunoturbidimetry detection reagent and method of a kind of cardic fatty acid binding protein | |
| CN105424620A (en) | Hydrolase method for measuring NG, NG<'>dimethyl-L-arginine or asymmetric dimethylarginine and kit | |
| CN114324865A (en) | Preparation method and application of creatine kinase isoenzyme detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170620 |